Mechanism of Action
Retinal Peptide Deficiency Correction
Normoftal operates on the Khavinson cytogen hypothesis: specific short peptide sequences accumulate in target tissues during development and decline with aging, contributing to tissue functional loss. Supplementing with the Lys-Glu sequence is proposed to correct this deficiency in retinal cells, restoring normal protein synthesis rates and cellular maintenance programs. The dipeptide is thought to enter retinal pigment epithelial (RPE) cells and photoreceptors via peptide transporters (PEPT1/PEPT2), where it activates promoter regions for retina-specific maintenance genes.
Gene Expression Regulation in Retinal Tissue
Consistent with the broader Khavinson chromatin-binding model, Lys-Glu is proposed to interact with histone complexes in retinal cells, activating transcription of genes governing photoreceptor maintenance, anti-apoptotic signaling, and RPE phagocytic clearance. Reduced apoptosis of photoreceptors and improved RPE function are the primary downstream effects documented in preclinical retinal models. Normalization of metabolic activity in retinal cells under oxidative stress conditions has also been reported.
Research Summary
Retinal Degeneration and Maculopathy
EmergingPreclinical studies from Khavinson's group show Lys-Glu peptide administration reduces photoreceptor apoptosis in aged rodent retinas and in models of oxidative retinal damage. Morphometric analysis showed preserved outer nuclear layer thickness and improved rod photoreceptor density in treated animals versus controls. Russian ophthalmological clinical experience reports subjective improvements in visual acuity and contrast sensitivity in patients with early age-related macular degeneration treated with periodic oral cytogen courses.
Retinopathy and Glaucoma Adjunct Use
EmergingClinical case series from Russian ophthalmology practices describe Normoftal use as adjunct therapy in diabetic retinopathy and glaucoma. In glaucoma patients, combination with conventional pressure-lowering therapy showed improved retinal nerve fiber layer preservation at 12 months compared to monotherapy controls in a small observational study. The mechanism proposed is neuroprotection of retinal ganglion cells via anti-apoptotic gene activation rather than intraocular pressure reduction.
Calculate your Normoftal dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Age-related macular degeneration | 2 capsules twice daily | 1 month; repeat after 2–3 months | Oral |
| Retinopathy (adjunct) | 2 capsules twice daily | 1 month course; 2–3x/year | Oral |
| Glaucoma support (adjunct) | 2 capsules twice daily | 1 month; 2x/year | Oral |
| Preventive / longevity | 2 capsules once daily | 1 month; repeat after 4–6 months | Oral |
Normoftal is an oral capsule supplement, no reconstitution required. Each capsule contains 0.275 g total (peptide + excipients). Take with water. Unlike injectable cytogens, oral bioavailability of Lys-Glu is partially reliant on gut peptide transporters; consistency of dosing timing may improve absorption.
Interactions
Safety Profile
Normoftal has a clean safety profile consistent with the Peptide Bio cytogen product line. Published research and clinical reports document no serious adverse events, no allergy reactions, and no organ toxicity. The oral capsule format is well tolerated with no gastrointestinal complaints reported in available literature. The Lys-Glu sequence is a naturally occurring dipeptide with no known pharmacological toxicity. As a dietary supplement, it falls outside prescription drug regulatory frameworks in most countries. Not WADA prohibited. Not FDA approved. No known drug interactions.
References
- [1]Khavinson VKh, et al. "Peptide regulation of gene expression and protein synthesis in retina." Bull Exp Biol Med. 2003;136(5):474-476.
- [2]Khavinson VKh, Linkova NS. "Mechanism of peptide regulation of genome." Bull Exp Biol Med. 2010;150(1):10-13.
- [3]e-peptide.com. "NORMOFTAL, Synthesized Retina Peptide." Peptide Bio product documentation. St. Petersburg: Peptide Bio, 2024.